Vitiligo is a cutaneous disorder of depigmentation, clinically characterized by well-demarcated, white macules of varying size and distribution. It can affect up to 2% of the population, especially younger ages. In spite of recent findings implicating genetic, immune and oxidative stress factors, the exact pathogenesis of vitiligo remains obscure. Here, we briefly discuss the prevailing theories, and offer new suggestions that could explain in part the damage of melanocyte in the vitiliginous lesions. Our emerging hypothesis is that neuropeptides released from peripheral nerve endings could synergize with new cytokines to adversely affect melanocyte function and viability. These may include corticotropinreleasing hormone (eRR) and neurotensin (NT), as well as interleukin 33 (IL-33) and thymic stromal lymphopoietin (TSLP). Such interactions could serve the basis for further research, possibly leading to new treatments.
Vitiligo is a cutaneous disorder of pigmentation, clinically characterized by hypopigmented, welldemarcated macules and patches with varying distribution throughout the body. The mean age of onset is i 5-25 years and its incidence varies worldwide from 0.5-2%, without predilection for sex or race.
In contrast to the ease of clinical diagnosis, the cellular and biochemical mechanisms that lead to the development of hypopigmented lesions in vitiligo are still unresolved. It was generally thought that the pigment-forming melanocyte is completely absent in affected areas. However, there is immunohistochemical evidence that in long-lasting disease some melanocytes are still present, but have lost their functionality (1) . Many theories have been proposed to explain the pathophysiology of vitiligo, but none provides a comprehensive mechanism to explain the disease and to offer potential targets for new treatments (2) . The aim of our review is to provide new insights into the cellular events possibly involved in vitiligo pathogenesis. multifactorial following a non-Mendelian pattern. A total of 17 susceptibility loci have recently been identified from three large genome-wide association studies of generalized vitiligo, encoding for immunomodulatory proteins that could participate in melanocyte death (3) . A recent paper showed that variation in the MHC class II region, and not in MHC I, is strongly associated with the age of onset in generalized vitiligo (4) , indicating that different loci may have different roles in disease susceptibility compared to the age of disease onset.
Another interesting genetic fact was the identification of a polymorphism for the thymic stromallymphopoietin (TSLP) gene -847C>T, which was found to increase susceptibility to generalized vitiligo by decreasing TSLP mRNA expression levels (5) . Moreover, a recent comprehensive association analysis of candidate genes for generalized vitiligo showed strong evidence of primary genetic association with vitiligo for TSLP (6), suggesting the important role of this gene in disease pathogenesis. TSLP is a cytokine structurally and functionally similar to interleukin-7 (IL-7) and has been implicated in conditions like asthma, allergic rhinitis and atopic dermatitis based on its ability to maintain immune homeostasis (7) .
SYSTEMIC EVENTS THAT CONTRIBUTE TO VITILIGO PATHOGENESIS

Autoimmunity
Most evidence supports immune-based melanocyte damage as the main etiologic pathway in vitiligo pathogenesis. Mainly, six autoimmune disorders have shown a strong genetic linkage with vitiligo: autoimmune thyroid disease (especially hypothyroidism-Hashimoto thyroiditis), pernicious anemia, Addison's disease, alopecia areata, diabetes mellitus type I and systemic lupus erythematosus (8) .
Both cell-mediated and humoral immunity appear to participate in the destruction of melanocytes. Histopathological investigations of the perilesional skin of vitiligo have suggested the involvement of T lymphocytes, mainly CD4+ and CD8+ T cells, in the disease process (9) . Interferon-gamma (IFNy) produced by Th-l cells increases angiogenesis through the expression of VEGF by both Th-l cells and keratinocytes (10) . VEGF, in tum, further induces angiogenesis and vascular permeability; it also induces polarization ofTh-l cells and increases the secretion ofIFN-y (10) . High levels of cytotoxic CD8+ T lymphocytes against gp100, Melan-A/ MART1 and tyrosinase antigens have been detected in HLA-positive vitiligo patients (11) . The release of inflammatory cytokines, especially interleukin-l (IL-l), interleukin-6 (IL-6), tumor necrosis factor (TNF) and IFN-y after skin trauma (e.g. Koebner phenomenon) might be an essential trigger that recruits T cells in the skin and exposes them to new antigen-expressing melanocytes (12) .
Antibodies to surface and cytoplasmic antigens of melanocytes found in vitiligo patients mainly belong to the IgG and IgA class (13) . The serum levels of these antibodies seem to correlate with the extent of the disease (13) . Antibodies binding to melanocytic antigens can induce melanocyte necrosis in vitro through antibody-dependent cellular cytotoxicity (ADCC) and complement activation (13) . Tyrosinase, the rate-limiting enzyme in melanin synthetic pathway, was suggested to be the principal auto-antigen in vitiligo (14) . Apart from tyrosinase, tyrosinase-related protein 1 (TRP 1), gp100 (PmeI17, melanosomal matrix protein) and MelanA/Martl, as discussed above, are also specific auto-antigens identified in vitiligo (13) . TRP 1 seems to be antibody related while Melan AlMART 1 and gp100 (PmeI17) are cytotoxic T cell related; tyrosinase is a combination of both. Recently, several B cell autoantigens have been identified using phage display methodology in patients with particularly nonsegmental vitiligo and include antigens to y-enolase, a-enolase, heat shock protein 90, osteopontin, ubiquitin-conjugating enzyme, translation initiation factor 2 and GTP binding protein Rab38 (15) . A recent paper using radioimmunoassay techniques indicated that tyrosine hydroxylase (TH) is another B-cell dependent auto-antigen involved in nonsegmental, but not in segmental vitiligo; levels of TH antibodies were more frequent in patients with active disease (16) .
Oxidative stress
Oxidative stress has been suggested as the initial event in the pathogenesis ofactive vitiligo, leading to lethal effects on melanocytes through the production of free radicals (17) . This hypothesis was based on the fact that some intermediates (dopaquinones and indoles) generated during melanin biosynthesis are toxic to melanocytes. Systemic oxidative stress in vitiligo patients may develop due to an imbalance in enzymatic and non-enzymatic antioxidant systems (17) . Low levels of catalase may contribute to the generation of oxidative stress in segmental vitiligo, while the generation of oxidative stress in nonsegmental vitiligo may be attributed to low levels of glutathione peroxidase and reduced glutathione (17) . In response to prolonged hydrogen peroxide (HP) exposure, the function of several proteins is affected including stress proteins, such as heat shock protein 70 (Hsp70), which normally prevent degradation of cellular proteins (18) . Once released into the extracellular environment, these stress proteins are very immunogenic, serving as auto-antigens.
Under the condition of altered redox status in vitiligo epidermis, keratinocytes not only decrease in number, but also seem to undergo vacuolar degeneration as a result of apoptosis, resulting in their inability to produce an adequate amount of melanocyte growth factors, such as stem cell factor (SCF), leading to melanocyte apoptosis (19) . SCF, released by keratinocytes, is essential for the survival of melanocytes and binds to the c-kit receptor on melanocytes. In addition, keratinocytes by themselves can release high amounts of proinflammatory cytokines, such as IL-6, IL-l and TNF. These cytokines can promote further inflammation by increasing the expression of the inter-cellular adhesion molecule 1 (ICAM-l) on the melanocyte membrane and by recruiting cytotoxic lymphocytes at sites of lesions (20) . ICAM-l can also induce Bcell activation, increasing auto-antibody formation and causing melanocyte damage, while TNF can directly interfere with mitochondrial functions within melanocytes through the production of peroxides, leading to mitochondrial-dependent cell death.
A generalized involvement of the epidermis has also been shown by a defective recycling of tetrahydrobiopterins (6BH 4 and 7BH 4 ) , associated with the intracellular production of HP2' In particular, 6BH 4 serves as the cofactor for both phenylalanine hydroxylase (PAR) and tyrosine hydroxylase (TH). Once formed, 6BH 4 is recycled by the rate-limiting enzyme 4a-hydroxy-6BH 4 -dehydratase (DH). DH activity is decreased in melanocytes of vitiligo patients, leading to the defective recycling of 6BH;1' which in tum promotes the formation of 7BH 4 (17); 7BH 4 can then inhibit PAH,causing the formation ofHP2' Increased 6BH 4 levels can also inhibit tyrosinase leading to defective melanin production (17) .
Neurochemical insults
The common symmetrical occurrence of vitiligo lesions suggests involvement of the neuronal system (21) . Moreover, there is considerable evidence that psychological stress can worsen or precipitate vitiligo (22) . Neurochemical mediators that are secreted by cutaneous axon terminals, such as norepinephrine (NE) and acetylcholine (Ach) are toxic to melanocytes. NE has direct melanocytotoxic effects by interfering with cellular sulfhydryl groups, impairing mitochondrial calcium uptake and inhibiting melanogenesis. Elevated levels of the NE degrading enzyme monoamine oxidase (MAO) in both melanocytes and keratinocytes in the depigmented skin result in the accumulation of toxic levels of HP2' with lethal effect on melanocyles (17) .
OTHER CELLULAR EVENTS THAT CONTRIBUTE TO VITILIGO PATHOGENESIS
There is morphological evidence supporting spetific melanocyte and keratinocyte abnormalities in itiligo, such as dilation of the endoplasmic reti ulum, vacuolar degeneration, cellular fragmentation and eterochromatic nuclei, all events related to apoptosis (19) . "Melanocytorrhagy" is another feature distinctive in vitiligo melanocytes. It refers to the chronic detachment and trans-epidermal loss of living melanocytes from the basal layer ofthe perilesional vitiligo skin following trauma or friction, resulting in eventual death of the detached pigment cells (23) . ROS can trigger the loss of dendrites of melanocytes, thus affecting melanosome transfer to surrounding keratinocytes. Oxidative stress can induce apoptosis in melanocytes (17) by releasing caspase-activating cytochrome c from mitochondria, a mechanism that involves the imbalance between Bax (pro-apoptotic protein) and Bcl-2 (anti-apoptotic protein) levels (17) . Microphthalmia transcription factor (MITF) dysregulation also plays an important role in inducing apoptosis in vitiligo skin. MITF expression is regulated downstream of the SCF/ c-kit linkage and serves as a transcription factor regulating the expression of tyrosinase mRNA (24) . It was recently reported that there is a close genetic relationship between MITF and Bcl-2 in human melanocytes (24) . As a result, a deficiency of MITF expression in melanocytes leads to apoptosis through the inactivation of the anti-apoptotic Bcl-2. Mutant alleles at SCF/ c-kit locus or at MITF locus can lead to mast cell deficiency since MITF has an essential role in mast cell function and development (25, 26) . Interestingly, a recent study reported the presence of increased numbers of mast cells in the center compared to the edge of vitiligo lesions, suggesting a role of mast cells in vitiligo pathogenesis (10) .
EMERGING HYPOTHESIS
Increasing evidence indicates that molecules such as interleukin 9 (IL-9) (27), interleukin 33 (IL-33) (28) and TSLP (29) are released following a number of insults and can activate many immune cells, especially mast cells. Given the recent report of the increased number of mast cells in the center of the vitiliginous skin (10), it is attractive to explore the possible associations ( Fig. I) between these inflammatory cytokines that could contribute to the initiation and/or the progression of the disease, either through or independently of mast cells, since a recent report did not show any increase in mast cell numbers in vitiligo (30) . For instance, IL-33 augments substance P (SP)-induced VEGF release from human mast cells (31) . SP can stimulate TNF secretion from mast cells (32) and a good correlation has been recently reported between serum TNF and the extent of vitiligo (33) . Apart from SP, corticotropin releasing hormone (CRR) secreted under stress, can activate local mast cells to release pro-inflammatory mediators (34) and could potentially trigger the release of melanin degrading and pro-apoptotic molecules, rendering the stressed skin vulnerable to hypopigmentation, especially since melanocytes have been reported to express corticotropin releasing hormone receptor-1 (CRRR-1) (43) . CRR and CRRR-1 are the central components of the hypothalamic-pituitary-adrenal (HPA) axis, an equivalent of which is present in the skin (35) . Recent evidence suggests that CRR in the periphery may have dual effects: a direct, short-term proinflammatory function and an indirect, remote antiinflammatory one, with different levels of feedback mechanisms involving downstream elements (36, 39) . Nevertheless, the potential involvement of CRR in the pathogenesis of skin inflammatory disorders was reviewed recently (37) .
Neuroimmune interactions are very important in mediating the effects of stress in the skin (38) and can also affect the vitiligo development process (39) . For instance, CRR and neurotensin (NT) were shown to act together increasing skin inflammation (40) , especially in those inflammatory skin diseases worsened by stress, including atopic dermatitis, psoriasis and urticaria (41, 42) . CRR in the skin upregulates the synthesis and secretion of proopiomelanocortin (POMe) and its peptides, with POMC being an important regulator ofmelanogenesis (39, 44) . Interestingly, mast cells have been reported to express POMC (45) . Melanocortin 1, one of the products of POMC maturation, evidently has a number ofvariants, including variants of its receptor on melanocytes (46) . A recent study showed that mRNA expression of POMC and its receptors, melanocortin receptor-1 (MC1R) and -4 (MC4R), is significantly decreased in lesional vitiligo skin, but increased in non-lesional vitiligo skin compared to healthy controls (47) . Nevertheless, no autoantibodies were identified in the blood of vitiligo patients that could have interfered with the action of a-melanocyte-stimulating hormone (a-MSH) on MC1R (48) .
Melanocyte expression of CRR, NT and its receptors along with those for IL-9, IL-33 and TSLP could shed light to the mechanism by which vitiligo skin lesions develop and are worsened with stress, leading to novel targets for the development of new treatments.
